Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Committee: NSCLC Study Should be Halted Due to Lack of Efficacy

Committee: NSCLC Study Should be Halted Due to Lack of Efficacy | Lung Cancer Dispatch | Scoop.it

"An independent data monitoring committee recommended that a phase 3 study designed to evaluate the combination of onartuzumab and erlotinib in a subset of patients with non–small cell lung cancer be stopped due to lack of clinically meaningful efficacy, according to a press release issued by the drugs’ manufacturer.


"The randomized, multicenter, double-blind, placebo-controlled MetLung study compared the humanized monoclonal antibody onartuzumab (MetMab, Genentech) plus the protein kinase inhibitor erlotinib(Tarceva, Genentech) vs. erlotinib alone in patients with previously treated advanced NSCLC whose tumors were MET-positive."

Cancer Commons's insight:

Healio  |  Mar 3, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Inhibition of MET May Help Overcome TKI Drug Resistance in Lung Cancer

Inhibition of MET May Help Overcome TKI Drug Resistance in Lung Cancer | Lung Cancer Dispatch | Scoop.it

Tyrosine kinase inhibitors (TKIs) that block EGFR are effective treatments for many cases of advanced non-small cell lung cancer (NSCLC), but are limited by the fact that patients will eventually develop resistance against them. Overexpression of the MET gene may contribute to EGFR-TKI resistance, suggesting that combined inhibition of both EGFR and MET may prevent or overcome this drug resistance. Several MET inhibitors have been developed, including cabozantinib (Cometriq), tivantinib, onartuzumab, and ficlatuzumab, and ongoing trials are investigating the safety and effectiveness of combining them with an EGFR-TKI like erlotinib (Tarceva) or gefitinib (Iressa).


Research paper: http://theoncologist.alphamedpress.org/content/early/2013/01/25/theoncologist.2012-0262.full.pdf

Cancer Commons's insight:

The Oncologist | Jan 28, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Effect of New Lung Cancer Drug Depends on MET Protein Expression Levels

Effect of New Lung Cancer Drug Depends on MET Protein Expression Levels | Lung Cancer Dispatch | Scoop.it

The cell protein MET is overexpressed in more than half of non-small cell lung cancer (NSCLC) tumors. MET overexpression is associated with worse prognoses and plays a role in drug resistance to EGFR inhibitors like erlotinib (Tarceva). A recent clinical trial examined the effects of onartuzumab, which inhibits MET function, on recurrent NSCLC. Patients received either onartuzumab and Tarceva or Tarceva only. In patients who overexpressed MET, adding onartuzumab increased the time until cancer progression and prolonged overall survival. In contrast, in patients without MET overexpression, adding onartuzumab worsened outcomes. This finding highlights the importance of diagnostic testing in choosing the best cancer treatment. A clinical trial investigating the onartuzumab-Tarceva combination in MET-overexpressing patients only is currently enrolling participants.

Cancer Commons's insight:

ASCO Post | Oct 10, 2013

more...
No comment yet.